SYMPOSIUM: ANTIMICROBIAL STEWARDSHIP (AMS): TODAY AND TOMORROW
09.20 - 09.40	Global epidemiology of antimicrobial resistance - S. Stefani (Italy)
09.40 - 10.00	Worldwide AMS programs at the time of COVID-19 - A. Brink (South Africa)
09.40 - 10.00	Role of PK/PD in AMS programs - R. Kozlov (Russia)
10.20 - 10.40	Avantages and disadvantages of AMS approaches - M.V. Villegas (Colombia)
10.40 - 11.00	Antifungal Stewardship - E. Bouza (Spain)
	ROUND TABLE: GENERAL RULES OF ANTIMICROBIAL USE IN CRITICALLY ILL PATIENTS
11.00 - 11.10	Risk stratification in empirical treatment - P. Montravers (France)
11.10 - 11.20	The importance of an appropriate empirical treatment - J.F. Timsit (France)
11.30 - 11.40	Role of new antimicrobials - D.P. Nicolau (Usa)
11.40 - 11.50	Role of old antibiotics - G. Dimopoulos (Greece)
	SYMPOSIUM: GRAM-NEGATIVE INFECTIONS AND ADEQUATE TREATMENT
12.00 - 12.15	ESBL and AmpC - Y. Carmeli (Israel)
12.15 - 12.30	CRE - F. Menichetti (Italy)
12.30 - 12.45	P. aeruginosa - S. Kanj (Lebanon)
12.45 - 13.00	A. baumannii - M. Bartoletti (Italy)
	SYMPOSIUM: FUNGAL INFECTIONS IN CRITICALLY ILL PATIENTS AND HEMATOLOGICAL PATIENTS
14.00 - 14.10	Aspergillosis - M. Akova (Turkey)
14.10 - 14.20	Invasive candidiasis - T. Calandra (Switzerland)
14.20 - 14.30	Rare fungal infection - O.Cornely (Germany)
14.30 - 14.40	Profilaxis of fungal infection in haemathologic patients - M. Mikulska (Italy)
14.40 - 14.50	Empirical and preempotive therapy in haemathologic patients - L. Pagano (Italy)
	SYMPOSIUM: UPDATE AND PERSPECTIVES ON DIAGNOSIS, PATHOGENESIS, CLINICAL AND THERAPEUTIC ASPECTS OF COVID – 19
15.00 - 15.15	New SARS-CoV-2 strain in South Africa with increased transmission potential - A. Brink (South Africa)
15.30 - 15.45	Update on clinical aspects of COVID-19 - C. Tascini (Italy)
15.45 - 16.00	Role of antivirals - M. Bassetti (Italy)
16.00 - 16.15	Role of corticosteroids and other antinflammatory agents - M. Kollef (Usa)
16.15 - 16.30	Role of Monoclonal Antibodies - G. Silvestri (Usa)
16.30 - 16.45	Role of ventilation - P. Pelosi (Italy)
15.00 - 15.15	Vaccine for COVID-19: Actual and future perspectives - G. Rezza (Italy)
	LECTURES
17.00 - 17.30	MRSA superinfection in COVID-19 patients - C. Tascini (Italy)
17.30 - 18.00	Progression in diagnostics in the management of infections - F. Arena (Italy)
18.00 - 18.30	Antibiotic treatment of ABSSSI and its complications - M. Dryden (UK)

	SYMPOSIUM: THERAPEUTIC OPTIONS IN SEVERE HOSPITAL INFECTIONS DUE TO RESISTANT MICROORGANISMS
09.00 - 09.30	COVID-19 pandemia influenced the epidemiology of MDR microorganisms? - A. Soriano (Spain)
09.30 - 10.00	Sepsis - M. Tumbarello (Italy)
10.00 - 10.30	HAP and VAP - D.P. Nicolau (USA)
	ROUND TABLE: OVERVIEW OF NEXT GENERATION ANTINFECTIVES AND PLACE IN THERAPY
11.00 - 11.10	New antibiotics for Gram positive - J. Garau (Spain)
11.10 - 11.20	New agents against C. difficile - M. Wilcox (UK)
11.20 - 11.30	New beta lactam/beta lactamase inhibitors - D.R. Giacobbe (Italy)
11.40 - 11.50	New cephalosporins - D.R. Giacobbe (Italy)
11.30 - 11.40	New antibiotics for CAP - A. Torres (Spain)
11.50 - 12.00	New antifungals - P. Munoz (Spain)
13.40 - 14.10	LECTURE   How to treat MDR Gram-Negative Infections - M. Bassetti (Italy)
	ROUND TABLE: PNEUMONIA: HOW TO UNDERSTAND THE ALPHABET SOUP?
14.10 - 14.20	CAP - A.Torres (Spain)
14.20 - 14.30	HAP - G. Poulakou (Greece)
14.30 - 14.40	vHAP - F. De Rosa (Italy)
14.40 - 14.50	VAP - J. A. Paiva (Portugal)
	SYMPOSIUM: DIFFICULT TO TREAT INFECTIONS (ABDOMINAL, ENDOCARDITIS, PROSTHETIC)
15.10 - 15.25	Abdominal infections - C. Eckmann (UK)
15.25 - 15.40	Necrotizing fasciitis - G. Dimopoulos (Greece)
15.40 - 15.55	Endocarditis - M. Falcone (Italy)
15.55 - 16.10	Meningitis and other CNS infections - N. Petrosillo (Italy)
16.10 - 16.25	Candidemia and invasive candidiasis - A. Vena (Italy)

MALATTIE INFETTIVE: GENOVA CAPITALE DELLA RICERCA